Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Breast Neoplasms 2043Neoplasms 1458Carcinoma, Non-Small-Cell Lung 1360Prostatic Neoplasms 1104Multiple Myeloma 870Leukemia, Myeloid, Acute 767Colorectal Neoplasms 710Neoplasm Metastasis 702Lung Neoplasms 696Melanoma 683Lymphoma 665Leukemia 595Lymphoma, Non-Hodgkin 592Leukemia, Lymphocytic, Chronic, B-Cell 535Ovarian Neoplasms 530Pancreatic Neoplasms 500Precursor Cell Lymphoblastic Leukemia-Lymphoma 483Recurrence 474Myelodysplastic Syndromes 424Lymphoma, Follicular 418Carcinoma, Renal Cell 410Head and Neck Neoplasms 407Glioblastoma 380Lymphoma, Large B-Cell, Diffuse 379Brain Neoplasms 374Hodgkin Disease 354Carcinoma, Hepatocellular 332Squamous Cell Carcinoma of Head and Neck 326Lymphoma, Mantle-Cell 306Sarcoma 286

Interventions

lanreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Flushing × Clear all
NCT00774930 2022-10-14

ELECT

Ipsen

Phase 3 Completed
115 enrolled 17 charts
EndocrineNET

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT01886287 2015-01-12

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 4 charts
EndocrineNET

Diarrhea, Flushing, Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡